BNET Industries
Market Cap:$3.7B
Last Fiscal Year Sales:$1.8B
- Public
- US
Dow Jones Description
Perrigo Company, established in 1887, is a leading global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and pharmaceutical and medical diagnostic products. The Company is the worlds largest manufacturer of OTC pharmaceutical products for the store brand market. The Companys primary markets and locations of manufacturing and logistics operations are the United States (U.S.), Israel, Mexico and the United Kingdom (U.K.). See Note 17 to the Companys consolidated financial statements for further information. Perrigo Company operates through several wholly owned subsidiaries. In the U.S., its operations are conducted primarily through L. Perrigo Company, Perrigo Company of South Carolina, Inc., Perrigo New York, Inc., Perrigo Holland, Inc. (formerly J.B. Laboratories, Inc.) and Perrigo Florida, Inc. (formerly Unico Holdings, Inc.). Outside the U.S., its operations are conducted primarily through Perrigo Israel Pharmaceuticals Ltd., Chemagis Ltd., Quimica y Farmacia S.A. de C.V., Laboratorios Diba, S.A., Wrafton Laboratories Limited, Brunel Pharma Limited (formerly Brunel Healthcare Ltd.) and Galpharm Healthcare Ltd. As used herein, references to the Company means Perrigo Company, its subsidiaries and all predecessors of Perrigo Company and its subsidiaries.
Number of Employees 6,200
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
Flu, economy boost drug maker Perrigo
-
Arkin investment NeurogesX gets FDA approval for patch: Mori Arkin owns 15% of the US...
-
Todays Zacks Rank Growth and Income Buy: Ross Stores, Inc.
-
NPI Watch - Nov. 2, 2009 - Editorial: Dr. Joshua Sharfstein at the Annual...
-
Perrigo Company Will Release First Quarter Fiscal 2010 Results on November 2, 2009
-
Bank of America Maintains a 'Buy' on Perrigo Company PRGO; Raises PT
-
UPDATE 1-Perrigo buys KV Pharma filing for generic acne gel
-
BUYINS.NET: 50.78% Of All NASDAQ Trading Tuesday Was Short Selling. BPSG, SHAW, ELOS, EXEL, PRGO,...
-
Expansion anticipated as Perrigo enters new fiscal year
-
Perrigo gears up for cough/cold season
-
Perrigo posts $144M profit
News & Analysis
Filter by
call transcript and perrigo co. - All News and Analysis
Perrigo Company F4Q09 (Qtr End 06/27/09) Earnings Call Transcript
Question-and-Answer Session Operator Operator Instructions The first question comes from the line of David Buck – Buckingham Research. David Buck – Buckingham Research First on Consumer Health can you talk about the level that you assumed in your guidance of price degradation if any and specifically...
Perrigo Company F3Q09 (03/28/09) Earnings Call Transcript
Question-and-Answer SessionOperator Operator instructions Your first question comes from the line of Greg Gilbert with Bank of America. Greg Gilbert – Bank of America Good morning. I have a few – nice to see some operating margin improvement versus last quarter even that vitamin drag but other than managing...
The Perrigo Company F2Q09 (Qtr End 12/27/08) Call Transcript
Question-and-Answer SessionOperator Operator Instructions. Our first question comes from the line of Daniel Rizzo with Sidoti & Company. Daniel Rizzo - Sidoti & Company I think you indicated and may be you already talked about this, but consumer or customers are lowering the inventories or lowered the inventories in...
Perrigo Co. F1Q09 (Qtr. End 09/30/08) Earnings Call Transcript
Question-and-Answer Session[Operator Instructions]. Your first question comes from the line of Greg Gilbert with Merrill Lynch. Gregory Gilbert - Merrill Lynch I have a few. Firstly, on new products... some $67 million in new products in the quarter, which I think compared to $75 million last quarter and $92...
- 1
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes

